A complement C3 test measures the concentration of complement component 3, a protein at the center of the classical, lectin, and alternative complement pathways. Because all three routes converge at C3, the result can reflect immune-complex activity, alternative-pathway activation, inflammation, impaired production, protein loss, or a rare inherited deficiency. Yet C3 is not a diagnosis in a tube: the same low value can arise for very different reasons, and a normal value does not rule out autoimmune or kidney disease.
Clinicians commonly order C3 with C4, CH50, urinalysis, kidney-function tests, and disease-specific antibodies. Interpretation depends on the laboratory’s reference interval, the clinical reason for testing, the pattern of related results, medications, and change from a person’s usual baseline. This article explains what the C3 number represents, why it may be high or low, how it is used in lupus and other immune disorders, and what follow-up can clarify an unexpected result.
- C3 is a central complement protein used by all major activation pathways.
- Low C3 can reflect consumption, reduced synthesis, protein loss, or rare inherited deficiency.
- High C3 is usually a nonspecific sign of increased production during inflammation or metabolic stress.
- C3 is most informative when interpreted with C4, CH50 or AH50, symptoms, and organ-specific testing.
- In lupus, trends may support assessment of disease activity, but normal C3 does not exclude a flare or lupus nephritis.
Table of Contents
- What the C3 blood test measures
- Normal range, units, and test preparation
- Why C3 levels become low
- What a high C3 result may mean
- C3 in lupus and other autoimmune disease
- Kidney disease and pathway-specific result patterns
- C3 deficiency and infection risk
- How to interpret, repeat, and follow the result
What the C3 blood test measures
C3 circulates mainly as an inactive protein. When complement is activated, enzymes called C3 convertases split it into fragments with different jobs. C3a contributes to inflammatory signaling. C3b attaches to microbial surfaces, damaged cells, and immune complexes, marking them for uptake by phagocytes and helping form enzymes that continue the cascade. Further breakdown products remain attached to targets or circulate and can be measured in specialized laboratories as evidence of activation.
The routine C3 blood test usually measures C3 antigen concentration, not how well C3 functions and not the amount of activated C3 fragments. Most clinical laboratories use immunochemical methods such as nephelometry or turbidimetry. The result therefore answers, “How much recognizable C3 protein is present in this sample?” It does not directly answer, “Is the protein structurally normal?” or “How much complement activation is happening at this moment?”
This distinction explains why a person can have a C3 concentration within range while complement is still activated. C3 is an acute-phase protein, so inflammation may increase production at the same time that activation consumes it. Those opposing forces can produce an apparently normal concentration. Conversely, a low concentration can persist after symptoms improve because replacement and regulation take time.
C3 sits downstream of C1q and C4 in the classical pathway, downstream of lectin recognition proteins in the lectin pathway, and at the amplification center of the alternative pathway. Comparing C3 with a C4 test helps estimate which pathways may be involved. Functional tests provide another layer: CH50 evaluates the classical-to-terminal sequence, while AH50 evaluates the alternative-to-terminal sequence.
C3 also has important roles beyond destroying microbes. It helps clear immune complexes and apoptotic material, shapes B-cell responses, interacts with coagulation and tissue repair, and influences kidney inflammation. Because it participates in so many processes, an abnormal C3 result is sensitive to broad immune activity but often lacks disease specificity.
Normal range, units, and test preparation
There is no universal C3 cutoff that applies to every laboratory. One large U.S. reference laboratory uses an adult serum interval of 75–175 mg/dL. Other laboratories may report approximately 80–180 mg/dL, use grams per liter, apply age-specific ranges, or establish different limits based on their assay and population. To convert conceptually, 100 mg/dL equals 1.0 g/L, but patients should not convert a report unless necessary; the laboratory’s own unit and interval are the authoritative comparison.
A “normal” result means the concentration falls within the statistical reference interval. It does not guarantee that complement regulation is normal, that C3 is fully functional, or that an autoimmune condition is inactive. A result near the low limit may be important if it has fallen sharply from the person’s baseline. A value below range may be less concerning if it has been stable for years and the clinical evaluation is reassuring, although persistent low C3 still deserves an explanation.
The test requires a venous blood sample. Special preparation is usually unnecessary, and fasting is generally not required for routine C3 measurement. The ordering laboratory may provide instructions when C3 is bundled with tests that do require preparation. Marked lipemia can interfere with some light-scattering methods, and specimen transport and storage requirements vary. A rejected, delayed, or compromised sample should be recollected rather than clinically overinterpreted.
Timing matters more for trends than for a single measurement. Ideally, serial tests used for disease monitoring are performed at the same laboratory, with the same method, and at comparable points relative to treatment. Acute infection, surgery, pregnancy, major inflammation, corticosteroids, immunosuppressive drugs, plasma therapy, and complement inhibitors can change the biological context.
A portal flag should be checked against the complete report. Confirm whether the sample was serum or plasma, whether the test was C3 concentration or C3 function, and whether the interval is appropriate for the patient’s age. Specialized results such as C3 nephritic factor, C3d, C3 split products, or soluble C5b-9 are not interchangeable with routine C3.
Why C3 levels become low
Low C3 develops when use or loss exceeds replacement, when production falls, or when a genetic defect prevents normal expression. The accompanying C4 and functional-test pattern helps sort these mechanisms.
Complement consumption
Immune complexes can activate the classical pathway and consume C3 along with C4. This occurs in active systemic lupus erythematosus, some immune-complex glomerulonephritides, cryoglobulinemic vasculitis, severe infection, and other inflammatory states. In lupus, both C3 and C4 may fall, although either can remain normal. A low result is more meaningful when it appears with compatible symptoms or organ abnormalities and reverses as disease activity improves.
Alternative-pathway dysregulation can consume C3 while leaving C4 relatively preserved. Examples include C3 glomerulopathy, atypical hemolytic uremic syndrome in selected contexts, dense deposit disease, and autoantibodies such as C3 nephritic factor that stabilize the alternative-pathway convertase. The pattern “low C3, normal C4” is a clue, not a diagnosis; infection and other causes can create the same combination.
Sepsis can drive intense complement activation and very low C3, sometimes alongside consumption of coagulation factors and other proteins. In this setting, the patient’s clinical condition, cultures, lactate, organ function, and inflammatory markers determine urgency. Complement testing does not replace infection management.
Reduced synthesis
The liver produces much of circulating C3. Advanced liver disease can reduce synthesis, particularly when hepatic function is severely impaired. Because liver disease also changes many plasma proteins, clinicians review albumin, coagulation tests, bilirubin, transaminases, and the overall clinical picture. Mild liver-enzyme elevations alone do not explain every low C3 result.
Severe malnutrition may also contribute to low protein production, although isolated low C3 is uncommon as the only sign. Systemic illness can simultaneously reduce production and increase consumption, making the mechanism mixed.
Protein loss
Heavy urinary protein loss in nephrotic syndrome, gastrointestinal protein loss, extensive burns, and other high-loss states can reduce complement proteins. Albumin and total protein often fall too. Kidney disease can therefore lower C3 by two routes: complement activation may consume it, while damaged glomeruli may allow protein loss. Urine protein quantification and biopsy findings help distinguish these processes.
Medication and treatment effects
Complement-targeted therapies intentionally alter pathway activity and may change concentrations or activation products in assay-specific ways. Plasma exchange, plasma infusion, or transfusion may temporarily remove or add complement proteins. Immunosuppressive treatment may raise C3 by reducing disease-driven consumption, but the timing varies. Clinicians need the exact drug, dose, infusion date, and assay method to interpret results safely.
Inherited deficiency or dysregulation
Complete C3 deficiency is rare. It usually presents early with recurrent, severe infections caused by encapsulated bacteria because C3b-mediated opsonization is crucial for microbial clearance. Partial deficiencies, dysfunctional C3, or defects in regulators can produce more variable infection, autoimmune, or kidney phenotypes. Persistent profoundly low C3, particularly with an abnormal functional pattern and characteristic history, should prompt specialist evaluation rather than repeated routine screening alone.
What a high C3 result may mean
C3 behaves as an acute-phase reactant. Cytokines released during inflammation can increase hepatic production, so C3 may rise during infection, tissue injury, or chronic inflammatory disease. A high value is therefore usually less diagnostically specific than a low one.
An elevated C3 can accompany acute or chronic infection, inflammatory bowel disease, some malignancies, obesity, insulin resistance, metabolic syndrome, and cardiovascular risk states. These associations do not mean that C3 causes the condition or that a high C3 result confirms it. The elevation may simply reflect broader inflammatory and metabolic signaling.
In a person being treated for an autoimmune disease, a rise from a previously low C3 toward the reference interval can indicate reduced complement consumption and may support clinical improvement. A value above the upper limit is not automatically “better,” however. Symptoms, organ tests, and other biomarkers must also improve. Steroids can suppress some inflammatory markers while affecting metabolism, and intercurrent infection can increase C3 despite active autoimmune disease.
Mild isolated elevation rarely requires a complement-focused workup. Clinicians generally assess the reason the test was ordered and review common contributors such as infection, obesity, smoking, diabetes, inflammatory conditions, and medication use. If the C3 is markedly high or accompanied by abnormal blood counts, liver tests, protein studies, or systemic symptoms, the broader abnormalities—not the C3 number alone—guide follow-up.
A high concentration also does not prove that the complement system functions efficiently. Functional deficiency can occasionally exist despite measurable antigen. When the clinical history strongly suggests a complement defect, CH50, AH50, and component-specific functional testing may be needed even if C3 concentration is normal or elevated.
C3 in lupus and other autoimmune disease
C3 and C4 are widely used in systemic lupus erythematosus because immune-complex activation can consume both proteins. Low complement is included among immunologic features considered in lupus classification, but classification criteria are not a substitute for clinical diagnosis. Many people with low C3 do not have lupus, and some people with established lupus maintain normal C3 during active disease.
For monitoring, the trend often matters. A fall from a stable baseline, especially with rising anti-double-stranded DNA antibodies, new rash, arthritis, cytopenias, serositis, or kidney abnormalities, can strengthen concern for a flare. Yet complement may lag behind symptoms, remain chronically low because of genetic copy-number variation or ongoing low-grade consumption, or normalize before organ inflammation fully resolves.
Kidney assessment deserves particular care. Lupus nephritis can be clinically quiet while urine protein or sediment worsens. Monitoring commonly includes blood pressure, serum creatinine and estimated glomerular filtration rate, urinalysis with microscopy, urine protein-to-creatinine ratio, C3, C4, and anti-dsDNA. A kidney biopsy may be needed to classify nephritis and separate active inflammation from chronic damage. The C1q test or anti-C1q antibodies may add context in selected patients, but they do not replace direct renal evaluation.
Other autoimmune and immune-complex conditions can lower C3, including cryoglobulinemic vasculitis, some rheumatoid vasculitis presentations, autoimmune hemolytic processes, and immune-complex glomerulonephritis. C4 may be disproportionately low in cryoglobulinemia because classical-pathway activation is prominent. In contrast, isolated C3 reduction draws attention toward alternative-pathway activation or certain kidney disorders.
C3 can be normal or high in inflammatory autoimmune disease because it is also an acute-phase protein. This is one reason clinicians do not use C3 as a general inflammation test. C-reactive protein, erythrocyte sedimentation rate, disease-specific antibodies, imaging, examination, and organ tests answer different questions.
Treatment decisions should never be based solely on “correcting” C3. The goal is control of the underlying disease and protection of affected organs. A patient whose C3 remains low but whose symptoms, urine, kidney function, and other markers are stable may need a different response from a patient whose C3 is only mildly reduced but whose creatinine and urine protein are rapidly worsening.
Kidney disease and pathway-specific result patterns
The kidney is both a target and a regulator of complement injury. Glomerular diseases can activate complement locally even when blood concentrations are normal. Conversely, a low serum C3 can be an important clue to the mechanism of glomerulonephritis.
| C3 pattern | Related findings | Interpretation to consider |
|---|---|---|
| Low C3 and low C4 | Low CH50, immune-complex symptoms, positive lupus serology | Classical-pathway consumption, including active lupus or immune-complex disease |
| Low C3 with normal C4 | Abnormal AH50, hematuria, proteinuria | Alternative-pathway activation, including infection-related GN or C3 glomerulopathy |
| Low C3 after infection that normalizes over weeks | Improving urine findings and kidney function | Transient postinfectious complement consumption may fit |
| Persistently low C3 with ongoing hematuria or proteinuria | Biopsy showing C3-dominant deposits | C3 glomerulopathy evaluation, including acquired and genetic regulators |
| Normal C3 and C4 with kidney abnormalities | Abnormal urine sediment or rising creatinine | Complement-mediated or lupus kidney disease is not excluded |
| Very low C3 plus low albumin and heavy proteinuria | Nephrotic-range protein loss | Consumption and urinary loss may both contribute |
In infection-related glomerulonephritis, C3 often falls and may recover as the infection and renal inflammation resolve. Failure to normalize within the expected clinical course raises concern for persistent infection, alternative-pathway dysregulation, or another diagnosis. The exact interval is individualized; clinicians do not rely on a fixed number of days without considering age, infection, biopsy, and trajectory.
C3 glomerulopathy is defined by kidney-biopsy findings showing dominant C3 deposition, not by serum C3 alone. Some patients have normal serum C3. Evaluation can include C3 nephritic factor, factor H and factor I studies, soluble membrane attack complex, genetic testing, monoclonal-protein assessment, and specialized complement analysis. These tests require expert interpretation because variants and autoantibodies may be risk factors rather than simple yes-or-no causes.
In membranoproliferative patterns, low complement helps narrow mechanisms but does not replace investigation for infection, autoimmune disease, monoclonal gammopathy, and other secondary causes. Kidney biopsy findings, immunofluorescence, and electron microscopy establish the tissue pattern that blood tests cannot.
The most urgent kidney clues are rising creatinine, falling urine output, rapidly increasing proteinuria, severe hypertension, edema, or active urinary sediment. A normal C3 should never reassure against these direct signs of renal injury.
C3 deficiency and infection risk
C3 is essential for opsonization—the coating of microbes so neutrophils and macrophages can recognize and ingest them efficiently. Complete inherited deficiency therefore creates a serious susceptibility to recurrent pyogenic infections, often beginning in infancy or childhood. Common organisms include encapsulated bacteria such as Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria species. Infections may involve the respiratory tract, bloodstream, meninges, joints, or other sites.
The clinical pattern differs from isolated terminal complement deficiencies, which are especially associated with recurrent meningococcal infection. Because C3 sits upstream of multiple effector functions, complete deficiency can impair opsonization and downstream membrane attack complex formation. Autoimmune and immune-complex complications may also occur because clearance is defective.
A low routine C3 value does not automatically mean inherited C3 deficiency. Acquired consumption is far more common. Features that increase suspicion include a profoundly reduced or undetectable level on repeated samples, abnormal CH50 and AH50, onset of severe infections early in life, infections despite appropriate vaccination, consanguinity, or similarly affected relatives. Component-specific functional testing and molecular analysis may be required.
Management is individualized by an immunologist or infectious-disease specialist. It can include prompt evaluation and treatment of fever, vaccination against encapsulated bacteria, review of vaccine antibody responses, education about meningitis and sepsis symptoms, and preventive antibiotics in selected patients. Vaccines reduce risk but may not eliminate it, especially when complement-mediated killing or opsonization remains impaired.
Anyone with a confirmed complement deficiency should seek urgent care for fever with severe headache, neck stiffness, a rapidly spreading non-blanching rash, confusion, breathing difficulty, low blood pressure, or rapid deterioration. Family members should not be screened solely because one relative has a mildly low C3; testing becomes appropriate after a true inherited defect is established and genetic counseling defines who is at risk.
How to interpret, repeat, and follow the result
Begin with the clinical question. Was C3 ordered to monitor known lupus, evaluate hematuria, investigate recurrent infections, or clarify an abnormal CH50? The same number has different significance in each setting.
Next, review the full complement pattern. Low C3 with low C4 suggests a different mechanism from low C3 with normal C4. CH50 and AH50 indicate whether whole pathways can function. A component concentration cannot identify every functional defect, and a functional screen cannot show which protein is responsible without follow-up testing.
Compare with direct disease measures. For suspected kidney inflammation, examine urinalysis, urine protein, creatinine/eGFR, blood pressure, and biopsy findings. For infection, consider cultures, blood count, inflammatory markers, imaging, and clinical severity. For liver or protein-loss disorders, review albumin, total protein, liver function, and urine or gastrointestinal losses.
Check timing and treatment. Record infections, vaccinations, flares, pregnancy, surgery, plasma products, immunosuppressive changes, and complement inhibitors. Do not stop medication to obtain a “cleaner” result unless the prescribing clinician specifically directs it; interrupting therapy can be dangerous.
Repeat testing is reasonable when a result is unexpected, near the cutoff, inconsistent with the clinical picture, or potentially affected by a specimen problem. Use the same laboratory when possible. A persistent abnormality carries more weight than a single isolated flag, but serial testing should have a defined purpose rather than being repeated until a preferred number appears.
Ask the clinician what would change management. Useful questions include: Is the C3 low because it is being consumed or because production is reduced? Does the C4 pattern suggest a pathway? Are kidney tests or infection history more concerning than the complement value? Is specialized complement testing warranted? Which symptoms require urgent assessment?
Seek prompt care for new blood in urine, foamy urine, swelling, markedly reduced urine output, chest pain, severe shortness of breath, or very high blood pressure. Seek emergency care for signs of meningitis, sepsis, airway swelling, confusion, or rapidly worsening illness. For most mildly abnormal C3 results, the next step is not an emergency—it is careful pattern-based interpretation with the clinician who ordered the test.
References
- Complement C3, Serum. 2026. Laboratory test guidance.
- Complement component 3 (C3). 2025. U.S. National Library of Medicine medical encyclopedia.
- 2024 American College of Rheumatology Guideline for Screening, Treatment, and Management of Lupus Nephritis. 2025. Clinical practice guideline.
- KDIGO 2024 Clinical Practice Guideline for the Management of Lupus Nephritis. 2024. Clinical practice guideline.
- Immunodeficiency: Complement disorders. 2024. Clinical review.
- The Complement System and Human Autoimmune Diseases. 2023. Review article.
Disclaimer
This article provides general education and is not a substitute for individualized medical advice, diagnosis, or treatment. C3 results must be interpreted using the performing laboratory’s range and the patient’s symptoms, medications, medical history, and related tests. Seek urgent medical care for severe infection symptoms, breathing difficulty, rapidly worsening swelling, markedly reduced urine output, or other signs of acute organ injury.
